Elevation in Serum Concentration of Bone-Specific Alkaline Phosphatase without Elevation in Serum Creatinine Concentration Secondary to Adefovir Dipivoxil Therapy in Chronic Hepatitis B
Virus Infection
Table 2
Clinical characteristics of 19 well-matched pairs of ADV group and non-ADV group at the time of enrollment obtained by propensity score.
Median (range)
value
ADV group ()
Non-ADV group ()
At the time of enrollment
Age (yr)
42 (29–68)
45 (34–68)
0.8940
Sex (male/female)
14/5
14/5
0.7126
HBV genotype (A/B/C/F/n.d)
1/3/11/1/3
1/4/10/0/4
0.7945
HBV DNA (log10 copies/mL)
2.1 > (negative–2.6)
2.1 > (negative–3.2)
0.2868
Platelet count (×103/m3)
16.2 (10.2–31.0)
16.0 (9.8–28.3)
0.1675
ALT (IU/L)
26 (15–49)
25 (9–60)
0.8742
Alb (g/dL)
4.4 (4–5.3)
4.4 (3.9–5.3)
0.8714
Cirrhosis (presence/absence)
5/14
5/14
0.7126
Child Pugh score of cirrhosis cases
All 5 cases: 5
All 5 cases: 5
At the time of starting ADV or ETV
Serum creatinine (mg/dL)
0.8 (0.6–1.2)
0.78 (0.57–1.2)
0.7692
Follow-up duration (month)
96 (29–134)
90 (55–102)
0.1323
Duration of nucleos(t)ide analogue therapy (month)
96 (29–134)
90 (55–102)
0.1323
Duration of Adefovir administration (month)
73 (12–107)
Propensity score
0.197 (0.068–0.553)
0.205 (0.067–0.514)
0.8267
ADV: adefovir dipivoxil; non-ADV: lamivudine or entecavir.
